CAS 162401-32-3|3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide|3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide|Roflumilast|Daxas|B ...

General Information

Structure

Molecular Formula

C₁₇H₁₄Cl₂F₂N₂O₃

Molecular Mass

403.2074664

Exact Mass

402.03495412

Charge

InChI

InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)

InChIKey

MNDBXUUTURYVHR-UHFFFAOYSA-N

Canonic Smiles

FC(Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl)F

Isomeric Smiles

n1cc(c(c(c1)Cl)NC(=O)c1ccc(c(c1)OCC1CC1)OC(F)F)Cl

Calculated Properties

JChem

Acid pKa

8.182302

H Acceptors

H Donor

LogD (pH = 5.5)

4.4463134

LogD (pH = 7.4)

4.384677

Log P

4.4475408

Molar Refractivity

93.9215

Polarizability

35.35955

Polar Surface Area

60.45

Rotatable Bonds

Lipinski's Rule of Five

true

Data Source

Commercial Catalog

Academic Data

Data Source

Names and Identifiers

IUPAC name

3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide

Synonyms

DaxasRoflumilastBYK 20869BY 217B 9302-1073-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide

IUPAC Traditional name

3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide roflumilast

Names and Identifiers

Registration numbers

PubChem CID

449193

PubChem SID

162037767

CAS Number

162401-32-3

Registration numbers

Properties

Product Information

Salt Data

Free Base

Certificate of Analysis

Download link

Safety Information

Storage Condition

-20°C

-20°C Freezer

MSDS Link

Download link

Physical Property

Chlorform

DMSO

154-158°C

White to Off-White Solid

Properties

Related Proteins

No Data Available

Click here to submit data

Molecular Spectra

No Data Available

Click here to submit data

Molecule Details

Selleck Chemicals

S2131

Research Area: Metabolic Disease
Biological Activity:
Roflumilast(Daxas) is a selective, long-acting the enzyme PDE-4 inhibitor with an IC50 of 0.8 nM. [1] It has antiinflammatory effects and is under development as an orally administered drug for the treatment of inflammatory conditions of the lungs such as asthma, and chronic obstructive pulmonary disease. While roflumilast was found to be effective in clinical trials, it produced several dose-limiting side effects including nausea, diarrhoea and headache, and development is continuing in an attempt to minimise the incidence of side effects while retaining clinical efficacy. [2][3]

TRC

R639700

Selective phosphodiesterase 4(PDE4) inhibitor. Antiasthmatic; in treatment of chronic obstructive pulmonary disease.

Molecule Details

References

PubChem Literature

From Data Sources

• http://en.wikipedia.org/wiki/Roflumilast

• Timmer, W., et al.: J. Clin. Pharmacol., 42, 297 (2001)

• Schmidt, B.M.W., et al.: J. Allergy Clin. Immunol., 108, 530 (2001)

• Rabe, K.F., et al.: Lancet, 366, 563 (2001)

• Hatzelmann, A., et al.: J. Pharmacol. Exp. Ther., 297, 267 (2001)